Please assess the completion status of the following clinical trial:

Trial Title: Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologically confirmed diagnosis of 1 of the following:~  * Acute myeloid leukemia (AML)~ * Myelodysplastic syndromes~    * Intermediate- or high-risk disease~ * Myelofibrosis~ * Granulocytic sarcoma (chloroma)~    * With or without bone marrow involvement~ * Mixed lineage leukemia~    * Induction therapy must have been directed predominantly against AML~ * Acute lymphoblastic leukemia~ * Non-Hodgkin lymphoma~ * Multiple myeloma~* Relapsed or refractory disease with M3 marrow (marrow blasts \> 25%), meeting 1 of the following criteria:~  * Persistent disease after an induction attempt~ * Persistent initial disease after two induction attempts~ * Relapse after one re-induction attempt (second relapse)~ * Persistent disease after first relapse and initial re-induction attempt~* Not eligible for myeloablative allogeneic hematopoietic stem cell transplantation due to age (\> 50 years), organ insufficiency, or significant comorbidity~  * Patients 16-50 years of age must meet ≥ 1 of the following criteria:~    * Ejection fraction 50-60% by MUGA scan and/or echocardiogram~   * DLCO 50-75% of predicted~   * Creatinine clearance or GFR 60-80 mL/min~   * Serum bilirubin ≤ 2.0 mg/dL~   * SGOT and SGPT 1.5-5 times upper limit of normal~   * No other medical and/or psychosocial problem that, in the opinion of the primary physician or principal investigator, would place the patient at unacceptable risk from study regimen~* No Fanconi anemia~* HLA-identical sibling OR matched unrelated donor available~PATIENT CHARACTERISTICS:~* Zubrod or Karnofsky performance status 70-100%~* Negative pregnancy test~* Able to lie supine in a full body cast for 30 minutes~* No HIV infection~* No evidence of active hepatitis B or C infection~* No evidence of cirrhosis~* No uncontrolled viral, bacterial, or fungal infection within the past 4 weeks~* No radiographic changes indicating pulmonary disease (e.g., pulmonary nodules, infiltrates, or pleural effusion) unless cleared by pulmonary biopsy that shows no evidence of active pulmonary disease~* No major medical or psychiatric disorder that would seriously compromise patient tolerance of study regimen~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radiation therapy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).